Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants

Study summary

RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at biomarkers for lung cancer using tissue samples from patients with lung cancer and from healthy participants.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedcomparative genomic hybridization and fluorescence in situ hybridization

Plus 8 other study approaches.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 20, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Vanderbilt University Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Vanderbilt University Medical Center
Interventions being studied: Genetic: comparative genomic hybridization; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: medical chart review; Procedure: diagnostic bronchoscopy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Known or previously diagnosed lung cancer
Suspected lung cancer, including the following:
Completely resected stage I lung cancer (with no evidence of metastatic disease) for which patient is at risk for developing secondary disease
Suspected of having lung cancer due to clinical symptoms, such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough, and positive x-ray
Healthy volunteer PATIENT CHARACTERISTICS:
WBC ≥ 2,000/mm³ but ≤ 20,000/mm³
Platelet count ≥ 50,000/mm³
Not pregnant
No uncontrolled hypertension (i.e., systolic blood pressure \> 200 mm Hg, diastolic blood pressure \> 120 mm Hg)
No unstable angina
No known bleeding disorder
No other contraindications for white light bronchoscopic examination
No other contraindications for fluorescence examination PRIOR CONCURRENT THERAPY:
More than 3 months since prior fluorescent photosensitizing agents (hematoporphyrin derivatives)
More than 3 months since prior and no concurrent chemopreventative drugs (e.g., tretinoin)
More than 6 months since prior ionizing radiation treatment to the chest
More than 6 months since prior systemic cytotoxic chemotherapy
No concurrent anticoagulant therapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Vanderbilt-Ingram Cancer Center - Cool SpringsNashville, Tennessee
Vanderbilt-Ingram Cancer Center at FranklinNashville, Tennessee
Veterans Affairs Medical Center - NashvilleNashville, Tennessee
Vanderbilt-Ingram Cancer CenterNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 20, 2017. Always confirm current availability with the study team.

View original record ↗